OREXIN B - Research Grade Peptide

OREXIN B – Research-Grade Linear 28-Residue Peptide

For research purposes only. This product is supplied exclusively for scientific laboratory research and analytical purposes. It is not intended for human or animal use, consumption, clinical use or therapeutic application. It must not be used in any way that contravenes applicable laws or the requirements of the Medicines and Healthcare products Regulatory Agency.

• Research-grade synthetic human Orexin B peptide with batch documentation available where supplied
• Defined linear peptide sequence comprising 28 amino-acid residues
• C-terminally amidated peptide structure corresponding to human Hypocretin-2
• Cysteine-free structure containing no intramolecular disulphide bonds
• Supplied as lyophilised laboratory material in sealed flip-top headspace vials
• Batch identity, chromatographic purity, peptide content and analytical specifications stated in the applicable Certificate of Analysis
• Handled and supplied exclusively as a research-use laboratory material

All of our research peptides and related laboratory materials are supplied strictly for scientific research and laboratory use only. Each vial contains lyophilised material prepared to support controlled laboratory handling and storage. The stated nominal amount refers to the declared Orexin B peptide content of a single vial, subject to the applicable batch documentation. Where dissolution or reconstitution is required, the solvent, buffer, concentration, handling procedure and storage conditions stated in the applicable Certificate of Analysis, Safety Data Sheet or validated laboratory method should be followed. We do not provide advice or recommendations concerning dosage, administration or use in humans or animals.

Chemical and Structural Information:

• Product Name: OREXIN B
• Preferred Technical Name: Human Orexin-B
• Alternative Names: Hypocretin-2; HCRT-2; Hcrt2; human Orexin B
• Material Classification: Synthetic linear 28-residue peptide
• Sequence Length: 28 amino-acid residues
• Complete Peptide Sequence: H-Arg-Ser-Gly-Pro-Pro-Gly-Leu-Gln-Gly-Arg-Leu-Gln-Arg-Leu-Leu-Gln-Ala-Ser-Gly-Asn-His-Ala-Ala-Gly-Ile-Leu-Thr-Met-NH₂
• One-Letter Sequence: RSGPPGLQGRLQRLLQASGNHAAGILTM-NH₂
• Human Precursor Reference: Corresponds to residues 70–97 of the human hypocretin neuropeptide precursor
• Human Precursor Accession: UniProt O43612
• N-Terminal Structure: Free arginine amino terminus
• C-Terminal Structure: C-terminal methioninamide
• Cyclic or Linear Structure: Linear peptide
• Cysteine Content: None
• Disulphide-Bond Content: None; the human Orexin B sequence contains no cysteine residues
• CAS Number: 205640-91-1
• PubChem Compound Identifier: CID 90479794
• Molecular Formula: C₁₂₃H₂₁₂N₄₄O₃₅S
• Average Molecular Weight: Approximately 2899.36 g/mol
• Approximate Molecular Size: 2.90 kDa
• InChIKey: DHBREICAXZPFDD-WMQZXSDYSA-N
• Sulphur-Containing Residue: The single sulphur atom in the molecular formula is contributed by the C-terminal methionine residue
• Formula Basis: The molecular formula and molecular weight describe the uncountered, C-terminally amidated human Orexin B peptide without trifluoroacetate, acetate, residual water, solvents or formulation excipients
• Physical Form: Lyophilised laboratory material, as stated in the applicable batch Certificate of Analysis
• Appearance: White to off-white laboratory material, subject to confirmation in the applicable batch Certificate of Analysis
• Purity Specification: The applicable chromatographic purity result, analytical method and acceptance criterion are stated in the batch Certificate of Analysis
• Peptide-Content Specification: Net Orexin B peptide content should be distinguished from chromatographic purity and interpreted alongside water, counter-ion, residual-solvent and formulation results
• Human Sequence Confirmation: The complete human 28-residue sequence should be confirmed using the applicable supplier, synthesis and batch records
• Species Confirmation: Human Orexin B should be distinguished from rat, mouse, canine and other species variants, which may have different amino-acid sequences, molecular formulae and molecular weights
• C-Terminal Amidation Confirmation: Molecular-identity documentation should confirm the C-terminal methioninamide and distinguish it from a free carboxylic acid terminal structure
• Mass-Spectrometry Confirmation: Molecular identity should be supported by analytical mass data consistent with the specified human Orexin B molecular structure
• TFA Status: Trifluoroacetate is a counter-ion form rather than an exact synonym for Orexin B
• Chemical-Form Confirmation: The applicable Certificate of Analysis should identify whether the supplied laboratory material is the uncountered peptide, an Orexin B trifluoroacetate form, an acetate form or another counter-ion presentation
• Counter-Ion Specification: Trifluoroacetate, acetate or another counter-ion may affect the total supplied material mass and the calculated net peptide content
• Nominal Amount Basis: The applicable product specification should state whether the declared vial quantity is expressed as net Orexin B peptide equivalent or as total supplied salt-form material
• Oxidation Control: Oxidation of the C-terminal methionine residue is a distinct peptide-related quality attribute and should be assessed or controlled where required by the batch specification
• Residual-Solvent Specification: Applicable residual solvents arising from peptide synthesis, cleavage and chromatographic purification should be stated or controlled through the batch specification
• Related-Impurity Control: Deletion sequences, truncated peptides, incompletely amidated material, methionine oxidation products, incompletely deprotected sequences and other synthesis-related or process-related impurities are separate quality attributes
• Endotoxin Specification: The applicable bacterial endotoxin or lipopolysaccharide result, analytical method, reporting units, method-suitability controls and acceptance criterion should be stated in the batch Certificate of Analysis
• Analytical Interpretation: Molecular identity, amino-acid sequence, terminal amidation, chromatographic purity, net peptide content, methionine oxidation, water content, residual solvents, counter-ion content and bacterial endotoxin results are separate analytical measurements and should be interpreted together

✓ Batch documentation – Completed Certificate of Analysis documentation is provided where supplied for the applicable batch.
✓ Certificate of Analysis – Accessible through the product QR code where a completed batch-specific document has been published.
✓ Safety Data Sheet – Supplied to support appropriate laboratory handling, storage and regulatory compliance.
✓ Sequence documentation – The complete human 28-residue amino-acid sequence should be confirmed using the applicable batch and synthesis records.
✓ Terminal-modification documentation – C-terminal methioninamide should be supported by appropriate molecular-identity data.
✓ Mass-spectrometry documentation – Molecular identity should be supported by analytical mass data consistent with the specified Orexin B structure.
✓ Purity documentation – The reported chromatographic purity applies only to the analytical method and batch stated in the Certificate of Analysis.
✓ Peptide-content documentation – Net Orexin B peptide content should be distinguished from chromatographic purity and interpreted alongside water, counter-ion and residual-solvent results.
✓ Chemical-form documentation – The uncountered peptide, trifluoroacetate form, acetate form or other counter-ion presentation should be identified clearly in the applicable product and batch records.
✓ Oxidation-control documentation – Methionine oxidation should be assessed or controlled where required by the applicable research specification.
✓ Bacterial endotoxin documentation – The applicable bacterial endotoxin or lipopolysaccharide result should identify the test method, reporting units, method-suitability controls and acceptance criterion.
✓ Supplier documentation – Reviewed where supporting synthesis, purification and analytical records are supplied.
✓ Fast, reliable and trackable express delivery – Securely packaged and dispatched using insulated or temperature-managed packaging where required by the applicable transport and storage specification.

For Research Use Only
This product is supplied strictly for scientific research, laboratory analysis and experimental work. It is not intended for human consumption, animal use, clinical use, diagnostic use or any form of therapeutic application.

Orexin B Product Overview

Our Orexin B research-grade linear peptide, also known as human Hypocretin-2, is supplied for controlled scientific laboratory investigation, analytical method development, peptide characterisation, high-performance liquid chromatography assessment, mass-spectrometry workflows and reference-material comparison.

Mature human Orexin B comprises a defined linear sequence of 28 amino-acid residues corresponding to residues 70–97 of the human hypocretin neuropeptide precursor. It has a free N-terminal arginine and a C-terminal methioninamide. Unlike Orexin A, Orexin B contains no cysteine residues and therefore has no intramolecular disulphide bonds.

The material is handled with a focus on batch traceability, documented quality control and consistent laboratory presentation. Product identity, species sequence, terminal amidation, chromatographic purity, net peptide content, molecular form, counter-ion content, water content, residual solvents, methionine oxidation, bacterial endotoxin results and other analytical specifications should be confirmed using the applicable batch Certificate of Analysis.

The CAS number 205640-91-1, molecular formula C₁₂₃H₂₁₂N₄₄O₃₅S and average molecular weight of approximately 2899.36 g/mol describe the uncountered, C-terminally amidated human Orexin B peptide. Where the supplied laboratory material contains trifluoroacetate, acetate or another counter-ion, the applicable batch documentation should identify its contribution to the total material mass.

“Human Orexin B TFA” describes a trifluoroacetate presentation rather than an alternative name for every Orexin B batch. The applicable product documentation should therefore distinguish the peptide identity from its counter-ion form and state whether the declared vial quantity represents net peptide equivalent or total salt-form material.

Chromatographic purity should not automatically be interpreted as equivalent to total net peptide content. Likewise, a bacterial endotoxin or lipopolysaccharide result does not establish sterility, molecular identity, correct terminal amidation, species identity or the absence of every peptide-related and process-related impurity.

For the majority of routine analytical, chromatographic, peptide-characterisation and general laboratory work, the Regular Orexin B specification remains highly suitable. The premium black-and-gold ULTIMATE Orexin B option provides an additional preparative high-performance liquid chromatography purification stage and a more stringent bacterial endotoxin and lipopolysaccharide testing specification for scientific projects requiring enhanced quality-control parameters.

View Certificate of Analysis

View Safety Data Sheet